- Home
- TXN vs NVO Comparison
TXN vs NVO Comparison
Compare TXN & NVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TXN | NVO |
|---|---|---|
| Founded | 1930 | 1923 |
| Country | United States | Denmark |
| Employees | N/A | 69500 |
| Industry | Semiconductors | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 181.9B | 197.4B |
| IPO Year | 2001 | N/A |
Fundamental Metrics
Financial Performance| Metric | TXN | NVO |
|---|---|---|
| Price | $307.35 | $45.62 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 25 | 11 |
| Target Price | ★ $265.46 | $51.00 |
| AVG Volume (30 Days) | 6.3M | ★ 12.6M |
| Earning Date | 04-22-2026 | 05-06-2026 |
| Dividend Yield | 2.11% | ★ 3.19% |
| EPS Growth | ★ 4.81 | N/A |
| EPS | ★ 1.68 | N/A |
| Revenue | ★ $17,682,000,000.00 | N/A |
| Revenue This Year | $11.74 | N/A |
| Revenue Next Year | $10.43 | $3.70 |
| P/E Ratio | $188.96 | ★ $13.60 |
| Revenue Growth | ★ 13.05 | N/A |
| 52 Week Low | $152.73 | $35.12 |
| 52 Week High | $331.51 | $81.44 |
Technical Indicators
Market Signals| Indicator | TXN | NVO |
|---|---|---|
| Relative Strength Index (RSI) | 62.92 | 60.45 |
| Support Level | $178.78 | $45.62 |
| Resistance Level | $310.29 | $50.30 |
| Average True Range (ATR) | 10.49 | 1.02 |
| MACD | -1.55 | -0.20 |
| Stochastic Oscillator | 47.61 | 47.84 |
Price Performance
Historical ComparisonAbout TXN Texas Instruments Incorporated
Dallas-based Texas Instruments generates over 95% of its revenue from semiconductors and the remainder from its well-known calculators. Texas Instruments is the world's largest maker of analog chips, which are used to process real-world signals such as sound and power. Texas Instruments also has a leading market share position in processors and microcontrollers used in a wide variety of electronics applications.
About NVO Novo Nordisk A/S
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.